BackNewAmsterdam Pharma Company NV Overview

NewAmsterdam Pharma Company NV Receivables

Track NewAmsterdam Pharma Company NV's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average

Loading

NewAmsterdam Pharma Company NV Receivables History

Loading

NewAmsterdam Pharma Company NV vs. peers: Receivables Comparison

Loading

NewAmsterdam Pharma Company NV Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NewAmsterdam Pharma Company NV (NAMS) FAQ

As of the most recent data (March 2026), NAMS shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NAMS's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether NewAmsterdam Pharma Company NV is outperforming or lagging.

Tracking NAMS's receivables over time shows whether NewAmsterdam Pharma Company NV is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has NewAmsterdam Pharma Company NV's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.